Symbols

EIKN

Eikon Therapeutics·NASDAQ

--(--)

3.80 / 10

Netural

Analyst coverage is mixed: two‑thirds rate Buy, one‑sixth Strong Buy, and one‑sixth Sell, yielding a low weighted rating of 0.46 and a pessimistic market outlook as the price fell 17.9%. Fund‑flow scores are solid (7.14/10), though inflows are declining across all investor sizes.

Fund Flow Rating

Analyst RatingBuy

Wall Street Opinions

Buy

Strong Buy

17%

Buy

67%

Hold

Sell

17%

Strong Sell

Date2026-03-02

InstitutionJP Morgan

Times predicted1

Historical Win Rate0.0%

What is the market sentiment for EIKN?

EIKN holds a Bearish analyst rating, with 67% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.80/10 (Netural).